NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$71.05
-10.39 (-12.76%)
Close of Nov 06, 2026 · end-of-day data
GMED 8-K filings, explained
Every material Form 8-K Globus Medical has filed with the SEC since February 06, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, representing a 0.7% decrease compared to the same period in 2025, alongside GAAP net income of $141.2 million. The company updated its full-year 2026 revenue guidance to $3.09 billion and announced a $500 million increase to its share repurchase program.
Worldwide net sales were $763.7 million for the third quarter ended September 30, 2026, down 0.7% year-over-year.
GAAP diluted earnings per share increased 18.2% to $1.04 for the quarter.
The Board authorized an additional $500.0 million share repurchase program increase on November 2, 2026.
Full-year 2026 revenue guidance was updated to $3.09 billion.
Globus Medical reported second-quarter 2026 worldwide net sales of $789.6 million, up 5.9%, and raised its full-year 2026 non-GAAP diluted EPS guidance to $4.95 to $5.05 from $4.70 to $4.80. GAAP diluted EPS fell 26.2% to $1.10, mainly because of a $110.5 million bargain purchase gain recorded in the prior-year quarter related to the Nevro acquisition. Full-year 2026 revenue guidance of $3.18 billion to $3.22 billion was reaffirmed.
Q2 2026 worldwide net sales were $789.6 million, up 5.9% as reported and 5.6% on a constant currency basis.
Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86; GAAP diluted EPS was $1.10, down 26.2% from $1.49.
Full-year 2026 non-GAAP diluted EPS guidance raised to $4.95 to $5.05 from $4.70 to $4.80.
Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion.
At its June 3, 2026 annual meeting, Globus Medical stockholders approved an amendment raising the shares authorized under its 2021 Equity Incentive Plan by 1,000,000, to 12,000,000 Class A shares. Stockholders also re-elected director Keith W. Pfeil and elected Robert A. Douglas to Class II terms, ratified Deloitte & Touche LLP as auditor for 2026, and approved executive compensation on an advisory basis.
Equity plan amendment: 246,228,534 for, 75,266,538 against, 79,135 abstain, 6,902,949 broker non-votes
Total shares authorized under the plan rise to 12,000,000 from 11,000,000 for incentive stock options, which are now 12,000,000
Director votes: Keith W. Pfeil 293,453,432 for and 28,120,775 withheld; Robert A. Douglas 311,683,904 for and 9,890,303 withheld
Deloitte & Touche LLP ratified for fiscal year ending December 31, 2026, with 327,965,803 for and 467,955 against
Globus Medical reported first-quarter 2026 net sales of $759.9 million, up 27.0% from a year earlier, and GAAP net income of $124.3 million, up 64.7%. The company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.70 to $4.80 from $4.40 to $4.50.
Q1 2026 net sales were $759.9 million, up 27.0%; base business excluding Nevro rose 13.2% to $677.2 million
GAAP diluted EPS was $0.90 versus $0.54 a year earlier; non-GAAP diluted EPS was $1.12 versus $0.68
Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion
Non-GAAP diluted EPS guidance raised to $4.70 to $4.80 from $4.40 to $4.50
Globus Medical director John A. DeFord, Ph.D., resigned from the Board of Directors effective immediately on March 23, 2026, and said the decision was not a result of any disagreement with the company. He will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. The filing describes a board departure with no change to financial results or guidance.
Resignation effective immediately, announced March 23, 2026
Company states the decision was not due to any disagreement with the company
Dr. DeFord would not have stood for re-election at the June 3, 2026 annual meeting
Chairman David C. Paul thanked him for his work on the NuVasive merger and the Nominating and Governance Committee
Globus Medical reported fourth-quarter 2025 worldwide net sales of $826.4 million, up 25.7%, and GAAP diluted EPS of $1.03 versus $0.19 a year earlier. The company reaffirmed 2026 revenue guidance of $3.18 to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.40 to $4.50 from $4.30 to $4.40. The sales growth includes the Nevro acquisition; the base business excluding Nevro grew 10.6% in the quarter.
Q4 2025 worldwide net sales were $826.4 million, up 25.7%; base business excluding Nevro rose 10.6%.
Q4 2025 GAAP net income was $140.6 million; GAAP diluted EPS was $1.03 versus $0.19 in Q4 2024.
2026 revenue guidance reaffirmed at $3.18 to $3.22 billion; non-GAAP diluted EPS guidance raised to $4.40 to $4.50 from $4.30 to $4.40.
Globus Medical said preliminary unaudited sales were about $823.2 million for the fourth quarter of 2025 and about $2.936 billion for full year 2025, up 25.2% and 16.5% on an as-reported basis. The company also set 2026 revenue guidance of $3.18 billion to $3.22 billion and non-GAAP diluted EPS of $4.30 to $4.40, though the figures remain subject to change until final results are released on February 24, 2026.
Q4 2025 sales of approximately $823.2 million, up 25.2% from Q4 2024 on an as-reported basis
Q4 2025 base business revenue, excluding Nevro, was $723.3 million, up 10.0%, led by US Spine
FY2025 sales of approximately $2.936 billion, up 16.5%; 2026 revenue guidance $3.18 billion to $3.22 billion
2026 non-GAAP diluted EPS guidance of $4.30 to $4.40; final results due February 24, 2026
Globus Medical reported second-quarter 2025 net sales of $745.3 million, up 18.4% from a year earlier, and GAAP net income of $202.8 million, compared with $31.8 million in the prior-year quarter. GAAP net income was lifted by a $110.6 million bargain purchase gain and a $34.8 million tax benefit, while the company reaffirmed its 2025 revenue and non-GAAP EPS guidance, so shareholders see a strong quarter whose GAAP profit is inflated by one-time items.
Q2 2025 net sales were $745.3 million, up 18.4% as reported and 17.6% on a constant currency basis.
The GAAP results include a $110.6 million bargain purchase gain and a $34.8 million tax benefit from a valuation allowance release.
The company reaffirmed 2025 revenue guidance of $2.80 billion to $2.90 billion and non-GAAP diluted EPS guidance of $3.00 to $3.30.
Daniel Scavilla resigned as Globus Medical's President, CEO and director effective July 18, 2025, to pursue another opportunity. The board named Keith Pfeil, the company's COO and CFO, as President and CEO and a director, and Kyle Kline as CFO, effective the same day. The company also reported preliminary second-quarter 2025 sales of approximately $745.3 million, up 18.4% as reported, and reaffirmed its full-year 2025 guidance.
Daniel Scavilla resigned as President, CEO and director effective July 18, 2025; the filing says the resignation was not due to any disagreement with the company.
Keith Pfeil was appointed President and CEO effective July 18, 2025, with his base salary rising to $490,000, prorated for 2025.
Preliminary Q2 2025 sales were approximately $745.3 million, up 18.4% as reported; base business sales were approximately $650.8 million, up 3.3%.
The company reaffirmed full-year 2025 revenue guidance of $2.80 billion to $2.90 billion and non-GAAP diluted EPS guidance of $3.00 to $3.30.
At its June 4, 2025 annual meeting, Globus Medical stockholders approved an amendment to the 2021 Equity Incentive Plan, effective that day, and elected four directors to three-year terms. Stockholders also ratified Deloitte & Touche LLP as auditor for 2025 and approved an advisory say-on-pay vote, and the board will now hold these pay votes every year. The results set the rules for equity awards and governance for shareholders going forward.
Equity plan amendment: 247,350,637 for, 76,025,441 against, 49,758 abstain; effective June 4, 2025
Directors elected to three-year terms: David C. Paul, Daniel T. Lemaitre, Leslie V. Norwalk, Ann D. Rhoads
Deloitte & Touche LLP ratified for fiscal year ending December 31, 2025, with 329,151,186 votes for and 689,046 against
Say-on-pay advisory vote approved with 315,631,443 for; stockholders favored annual votes (322,479,669 for 1 Year), and the board will hold them every year
Globus Medical reported first-quarter 2025 net sales of $598.1 million, down 1.4% from a year earlier, while GAAP net income rose to $75.5 million from a loss of $7.1 million. The company cut its full-year 2025 non-GAAP diluted EPS guidance to $3.00 to $3.30 from $3.10 to $3.40, but reaffirmed its full-year revenue guidance of $2.80 to $2.90 billion. Shareholders get a mixed picture: profit improved, but sales declined and the earnings outlook was lowered.
Net sales were $598.1 million, down 1.4% (down 0.8% on a constant currency basis); U.S. sales rose 0.2% while international sales fell 7.7%.
GAAP diluted EPS was $0.54, compared with a loss of $0.05 a year earlier; non-GAAP diluted EPS was $0.68, up from $0.63.
Full-year 2025 non-GAAP diluted EPS guidance was lowered to $3.00 to $3.30 from $3.10 to $3.40; revenue guidance of $2.80 to $2.90 billion was reaffirmed.
The company paid off the remaining $450 million of debt assumed from the NuVasive merger and reported free cash flow of $141.2 million.
Globus Medical completed its previously announced merger with Nevro Corp. on April 3, 2025, making Nevro a wholly owned subsidiary. Nevro shareholders receive $5.85 per share in cash, and Nevro stock stopped trading on the NYSE before the market opened that day.
Nevro common stock holders receive $5.85 per share in cash, without interest and subject to withholding taxes.
Nevro stock options were cancelled without consideration; RSUs and PSUs convert to cash payments at the Merger Consideration.
The Merger Agreement is dated February 6, 2025; Globus says the deal unlocks a $2 billion market opportunity in neuromodulation and beyond.
Globus plans to discuss the closing and expected benefits on its first quarter earnings conference call in May.
Globus Medical reported fourth-quarter 2024 net sales of $657.3 million, up 6.6% from a year earlier, and GAAP net income of $26.5 million, up from $15.0 million. For the full year, sales were $2.52 billion, up 60.6%, largely from the NuVasive merger, but GAAP net income fell to $103.0 million from $122.9 million. The company reaffirmed its stand-alone 2025 guidance and gave new guidance that includes the pending Nevro acquisition.
Q4 2024 GAAP diluted EPS was $0.19 versus $0.11; non-GAAP diluted EPS was $0.84 versus $0.60
Full-year 2024 GAAP diluted EPS was $0.75 versus $1.07 in 2023; non-GAAP diluted EPS was $3.04
Stand-alone 2025 revenue guidance of $2.66 billion to $2.69 billion reaffirmed; non-GAAP EPS guidance of $3.40 to $3.50
With Nevro acquisition, expected to close in late second quarter 2025, 2025 net sales guidance is $2.80 billion to $2.90 billion and non-GAAP EPS $3.10 to $3.40
Globus Medical agreed to acquire Nevro Corp. in an all-cash transaction valued at approximately $250 million in total equity value, subject to Nevro shareholder approval, regulatory clearance and other closing conditions. Globus Medical said that after the deal closes it expects higher 2025 net sales but lower non-GAAP earnings per share than its stand-alone guidance.
Nevro shareholders will receive $5.85 per share in cash, a 17% premium to Nevro's February 5, 2025 closing price.
Globus Medical expects the deal to close late in the second quarter of 2025 and anticipates the Nevro acquisition to be accretive to earnings in the second year of operation.
Post-deal 2025 guidance: net sales of $2.80 billion to $2.90 billion (versus stand-alone $2.66 billion to $2.69 billion) and non-GAAP EPS of $3.10 to $3.40 (versus stand-alone $3.40 to $3.50).
Termination fees: Nevro would pay $15 million or $10 million in certain circumstances, including a failed stockholder vote; Globus Medical would pay $15 million in certain circumstances.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Globus Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →